{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00810238",
      "OrgStudyIdInfo": {
        "OrgStudyId": "C3BS-C-07-01"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "EudraCT 2007-007699-40"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Celyad Oncology SA",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "C-Cure Clinical Trial",
      "OfficialTitle": "C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2012",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2008"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2010",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2012",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 17, 2008",
      "StudyFirstSubmitQCDate": "December 17, 2008",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 18, 2008",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "September 3, 2012",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 5, 2012",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Celyad Oncology SA",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this clinical trial is to evaluate the feasibility, safety and efficacy of left ventricular endocardial injection of guided bone marrow-derived cardiopoietic cells (C-Cure) in the setting of chronic heart failure secondary to ischemic cardiomyopathy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Heart Failure Class II or III"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Heart failure",
          "Cell therapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2",
          "Phase 3"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "240",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Optimal standard of care + C-Cure",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: C-Cure"
              ]
            }
          },
          {
            "ArmGroupLabel": "2",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Optimal standard of care"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "C-Cure",
            "InterventionDescription": "Intraventricular injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in left ventricular ejection fraction",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "6-min walking distance",
            "SecondaryOutcomeTimeFrame": "6 months, 1 and 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Quality of Life",
            "SecondaryOutcomeTimeFrame": "6 months, 1 and 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "All cause mortality",
            "SecondaryOutcomeTimeFrame": "Each follow-up"
          },
          {
            "SecondaryOutcomeMeasure": "Cardiovascular events",
            "SecondaryOutcomeTimeFrame": "Each follow-up"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubject is ≥ 18 and < 75 years old;\nSubject has Heart Failure, New York Heart Association (NYHA) class II or class III with LVEF > 15% and ≤ 40% as assessed by transthoracic echocardiography;\nSubject has ischemic heart disease;\nSubject has an identifiable (by transthoracic echocardiography) area of transmural scar within the left ventricle;\nSubject is on optimal and stable medical therapy for more than 2 months;\nSubject is willing and able to undergo an ICD implantation, prior to receiving C-Cure™ or already has an ICD implanted;\nSubject agrees to comply with all follow-up evaluations;\nSubject has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent.\n\nExclusion Criteria:\n\nSubject has been treated with cell-based therapy;\nSubject has myocardial revascularization by PCI or CABG within 2 months prior to enrolment;\nSubject has had an MI within 2 months prior to enrolment;\nSubject is planned for PCI, CABG or any cardiac surgery;\nSubject has received a biventricular pacemaker within 6 month prior to enrolment;\nSubject has moderate to severe aortic valve heart disease, aortic or mitral prosthetic valve;\nSubject has a significant mitral valve insufficiency (Effective Regurgitant Orifice (ERO) > 0.2 cm²) with possibility of mitral valve surgery;\nSubject has left ventricular thrombus;\nSubject has LV aneurysma or is a candidate for surgical aneurysmectomy;\nSubject LV ventricular wall thickness is < 5 mm in the target territory;\nSubject has proven high grade atrioventricular block or sustained ventricular tachyarrhythmias;\nSubject has an hemodynamically significant congenital heart disorder;\nSubject has clinical evidence for infection or active malignancy;\nSubject has known stable chronic kidney dysfunction with serum creatinine > 2.5 mg/dL at two occasions during the screening period;\nSubject has experienced severe adverse reaction/allergies to contrast agents;\nSubject has atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree, that could impede or preclude the safe retrograde passage of the delivery catheter, in the judgment of the investigator;\nSubject is on chronic immunosuppressive transplant therapy;\nSubject had an autologous or allogenic bone marrow or peripheral stem cell transplant or prior solid organ transplantation;\nSubject has a multisystem disease;\nSubject has been tested positive for Human Immunodeficiency Virus (HIV 1 or HIV 2), Hepatitis B Virus (HBV), Hepatitis C (HCV) and/or syphilis;\nWomen of child bearing potential;\nSubject has life expectancy < 1 year from non heart failure related causes;\nSubject suffers from morbid obesity (Body Mass Index (BMI) > 40);\nSubject has a recent history of alcohol or drug abuse;\nSubject has any other surgical or medical condition that, in the judgment of the investigator might warrant exclusion or be contraindicated for safety reasons;\nSubject is currently participating in another trial.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Jozef Bartunek, MD, PhD",
            "OverallOfficialAffiliation": "VZW Cardiovascular Research Center Aalst",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "André Terzic, MD, PhD",
            "OverallOfficialAffiliation": "Mayo Clinic, Rochester, USA",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "CardioVascular Center",
            "LocationCity": "Aalst",
            "LocationZip": "9300",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Université Catholique de Louvain, Saint-Luc",
            "LocationCity": "Brussels",
            "LocationZip": "1200",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Centre Hospitalier Universitaire",
            "LocationCity": "Charleroi",
            "LocationZip": "6000",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Universitair Ziekenhuis Antwerpen",
            "LocationCity": "Edegem",
            "LocationZip": "2650",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Ziekenhuis Oost Limburg",
            "LocationCity": "Genk",
            "LocationZip": "3600",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Virga Jesse Ziekenhuis",
            "LocationCity": "Hasselt",
            "LocationZip": "3500",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Centre Hospitalier Universitaire",
            "LocationCity": "Liège",
            "LocationZip": "4000",
            "LocationCountry": "Belgium"
          },
          {
            "LocationFacility": "Clinical Center of Serbia",
            "LocationCity": "Belgrade",
            "LocationZip": "11000",
            "LocationCountry": "Serbia"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23583246",
            "ReferenceType": "derived",
            "ReferenceCitation": "Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013 Jun 11;61(23):2329-38. doi: 10.1016/j.jacc.2013.02.071. Epub 2013 Apr 10. Erratum in: J Am Coll Cardiol. 2013 Dec 24;62(25):2457-8."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006333",
            "ConditionMeshTerm": "Heart Failure"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8573",
            "ConditionBrowseLeafName": "Heart Failure",
            "ConditionBrowseLeafAsFound": "Heart Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11306",
            "ConditionBrowseLeafName": "Cardiomyopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          }
        ]
      }
    }
  }
}